Amyloidosis Flashcards

1
Q

Define amyloidosis.

A

Describes the extracellular deposition of an insoluble fibrillar protein termed amyloid which is derived from many different precursor proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How is amyloidosis classified?

A
  • AL - amyloid light chain - contains Ig light chains derived from plasma cells
  • AA - serum amyloid A which is an acute-phase reactant produced in inflammation
  • A-beta - beta amyloid/APP(amyloid precursor protein) - found in Alzheimer’s disease
  • ATTR - transthyretin - TTR is a protein made in the liver which transports thyroxine and retinol binding protein. A mutant form of this protein is deposited in genetically determined familial amyloid neuropathies. TTR is also deposited in the heart —> senile systemic amyloidosis.

Many other types exist.

Effects can be localised or systemic:

  • Systemic e.g. AL, AA, A-beta
  • Localised e.g. A-beta, isolated atrial amyloidosis.

Also classified as primary or secondary:

  • Primary amyloidoses = from a disease with disordered immunity e.g. MM.
  • Secondary (reactive) amyloidoses= from complication of chronic inflammatory or tissue-destroying disease e.g. reactive systemic amyloidosis and secondary cutaneous amyloidosis.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Explain the pathophysiology of amyloidosis.

A
  • Amyloid is derived from many different precursor proteins
  • In addition to its fibrillar component it has a non-fibrillary protein called amyloid P, derived from the acute phase serum amyloid P
  • Other non-fibrillary components include apolipoprotein E and heparan sulfate proteoglycans
  • Accumulation of amyloid fibrils → tissue/organ dysfunction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the hallmarks of nephrotic syndrome?

A
  • Proteinuria
  • Hypoalbuminaemia
  • Oedema
  • Hyperlipidaemia (occurs because albumins and other proteins usually reduce lipid synthesis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe the pathophysiology of AL amyloidosis.

A

Plasma cell clones → amyloidogenic monoclonal immunoglobulins → fibrillar light chain deposition → organ failure → death.

This occurs in myeloma (15%), Waldenstrom’s, lymphoma.

  1. Kidneys: → deposits disrupting glomerular BM → proteinuria and nephrOtic syndrome
  2. Heart → idiopathic restrictive cardiomyopathy ( looks “sparkling” on echo) arrhythmias, angina.
  3. Nerves → deposits in vasa nervorum → peripheral and autonomic neuropathy + carpal tunnel.
  4. Gut → macroglossia, malabsorption, perforation, haemorrhage, obstruction, hepatomegaly.
  5. Vascular → purpura, especially periorbital, characteristic feature.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe the pathophysiology of AA (secondary) amyloidosis.

A

Derived from serum amyloid A, acute phase protein, e.g. in chronic inflammation in RhA, UC/Crohn’s, FMF, and chronic infections - TB, bronchiectasis, osteomyelitis. *

  • Affects kidneys, liver, spleen → proteinuria, nephrotic syndrome, hepatosplenomegaly.
  • Macroglossia is NOT seen
  • Cardiac involvement is RARE
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the pathophysiology of AF amyloidosis/ATTR.

A
  • Most common inheited, systemic form of amyloidosis
  • Autosomal dominant - due to mutations in transthyretin (TTR is a transport protein made by the liver) and each variant has a different organ involvement
  • Usually causes sensory or autonomic neuropathy, renal impairment, familial cardiomyopathy too.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is senile systemic amyloidosis (SSA)?

A
  • A form of amyloidosis associated with an unmutated (native/wild-type) TTR
  • Occurs in the elderly
  • Formely known as senile systemic cardiac amyloidosis
  • Deposition occurs exclusively in the heart
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Descirbe the epidemiology of amyloidosis.

A
  • RARE - 5-12 cases per million
  • Increasing prevalence of AL but decreasing AA due to better anti-inflammatories
  • Males>females
  • More common in black people
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the risk factors for amyloidosis?

A
  • MGUS - x8.4 risk
  • Inflammatory polyarthropathy e.g. RA, psoriatic arthritis, ankylosing spondylitis
  • Chronic infections - bronchiectasis, UTIs, osteomyelitis, decubitus ulcers
  • IBD especially Crohn’s
  • Familial periodic fever syndromes
  • Rare: Castleman’s disease (non-cancerous tumours of lymphoid tissue)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the presenting symptoms of amyloidosis?

A
  • Fatigue
  • Weight loss
  • Dyspnoea on exertion

Less common:

  • Paraesthesia (peripheral neuropathy)
  • Claudication
  • Nausea
  • Abdominal cramps
  • Alternating bowel habit
  • Orthostatic hypotension
  • Hepatomegaly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

List some signs of amyloidosis on examination.

A
  • Jugular venous distension
  • Lower extremity oedema
  • Periorbital purpura
  • Macroglossia
  • Submandibular salivary gland enlargement
  • Sensory neuropathy
  • Tinel’s sign (tapping carpal nerve → tingling in 1-4th fingers in carpal nerve syndrome)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What invesigations would you do for amyloidosis?

A

1st

  • serum immunofixation –> shows monoclonal protein presence
  • urine immunofixation –> same
  • immunoglobulin free light chain assay –> abnormal kappa to lambda ratio
  • bone marrow biopsy –>clonal plasma cells

Other:

  • tissue biopsy –> positive Congo Red staining. Apple-green birefringence is seen when Congo red stained material is viewed under polarised light. Can be taken from rectum or subcutaneous fat.
  • genetic testing - sequence for TTR, fibrinogen , lysozyme, TNFR1 etc genes.
  • ECG - conduction abnormalities
  • 24hr urine - proteinuria (>3g/24hr = nephrotic syndrome)
  • echocardiogram - diastolic dysfunction, thickening of interventricular septum
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Define AL amyloidosis.

A

Amyloid light chain amyloidosis

Caused when misfolded free light chains aggregate into amyloid fibrils in target organs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the main determinant for AL amyloidosis development?

A

Amyloidogenic potential of the light chain > their amount

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What types of light chain are most commonly involves in AL amyloidosis?

A

Lambda light chain (60%) e.g. IGLV6-57 in kidney, IGLV1-44 in cardiac.

17
Q

What are the clinical presentations of AL amyloidosis?

A
  • Nephrotic syndrome (70%) - proteinuria, peripheral oedema
  • Unexplained HF
  • Sensory neuropathy
  • Abnormal liver function tests
  • Macroglossia
18
Q

What investigations may help diagnose AL amyloidosis related HF?

A

NT-proBNP raised

Abnormal echo

Abnormal cardiac MRI

19
Q

What are the main two types of amyloidosis?

A

AA - derived from serum amyloid A e.g. Crohn’s, RhA

AL - derived from light chains of Ig e.g. in MM, B cell lymphoma

20
Q

Apart from light chains and serum amyloid A, what other proteins can give rise to amyloid?

A

Transthyretin e.g. mutation

B2-macroglobulin - peritoneal dialysis

AB2 protein - Alzheimer’s

Insulin, calcitonin - endocrine tumours

21
Q

What is the management of AL amyloidosis?

A

Referral to specialist amyloidosis centre

Suppress plasma clone responsible e.g.

  • Autologous stem cell transplant - if Mayo eligibility criteria are met; induction therapy is usually bortezomib based
  • +/- Systemic therapy - e.g. Dara-CyBorD chemotherapy or lenalidomide plus dexamethasone
22
Q

What is the management of AA amyloidosis?

A

Control the underlying systemic inflammatory process e.g.

  • TNF-alpha inhibitors e.g. infliximab, etanercept
  • IL-1 inhibitors e.g. anakinra
  • IL-6 inhibitors e.g. tocilizumab
  • Specific therapies:
    • Resect tumour in Castleman’s disease
    • Colchicine in FMF
23
Q

What are the complications of amyloidosis?

A
  • Treatment related complications e.g. SCT mortality is 2.5%, organ dysfunction post-chemo, infections, fluid-retention
  • CKD
  • Cardiomyopathy - MOST COMMON CAUSE OF DEATH in amyloidosis; restrictive so responds poorly
  • Conduction abnormalities
  • Painful peripheral neuropathy
  • Macroglossia obstruction
  • Factor X deficiency - due to advanced hepatic amyloidosis
  • Splenic rupture - as it becomes rigid
24
Q

What is the prognosis with amyloidosis?

A

AL - depends on therapeutic suppression of light chains; if suppressed 25% will survive for a decade

AA - also depends on control of disease; serum AA levels are highly predictive or survival e.g. <10mg/L associated with >10yr survival